2023
Older patients with chronic myeloid leukemia face suboptimal molecular testing and tyrosine kinase inhibitor adherence
Shallis R, Wang R, Zeidan A, Huntington S, Neparidze N, Stempel J, Mendez L, Di M, Ma X, Podoltsev N. Older patients with chronic myeloid leukemia face suboptimal molecular testing and tyrosine kinase inhibitor adherence. Blood Advances 2023, 7: 3213-3224. PMID: 36939371, PMCID: PMC10338212, DOI: 10.1182/bloodadvances.2022009074.Peer-Reviewed Original ResearchConceptsChronic myeloid leukemiaTKI adherenceTKI initiationOlder patientsMyeloid leukemiaEnd Results-Medicare databaseTyrosine kinase inhibitor usePolymerase chain reaction testingQuantitative polymerase chain reaction testingOlder patient populationCare of patientsHealth care accessReal-world studyReal-world evidenceLow socioeconomic statusLow-income subsidyFirst yearInfluenza vaccinationInhibitor useWorse survivalTKI treatmentMultivariable analysisPatient populationOptimal monitoringCare access
2019
Alisertib plus induction chemotherapy in previously untreated patients with high-risk, acute myeloid leukaemia: a single-arm, phase 2 trial
Brunner A, Blonquist T, DeAngelo D, McMasters M, Fell G, Hermance N, Winer E, Lindsley R, Hobbs G, Amrein P, Hock H, Steensma D, Garcia J, Luskin M, Stone R, Ballen K, Rosenblatt J, Avigan D, Nahas M, Mendez L, McAfee S, Moran J, Bergeron M, Foster J, Bertoli C, Manning A, McGregor K, Fishman K, Kuo F, Baltay M, Macrae M, Burke M, Behnan T, Wey M, Som T, Ramos A, Rae J, Lombardi Story J, Nelson N, Logan E, Connolly C, Neuberg D, Chen Y, Graubert T, Fathi A. Alisertib plus induction chemotherapy in previously untreated patients with high-risk, acute myeloid leukaemia: a single-arm, phase 2 trial. The Lancet Haematology 2019, 7: e122-e133. PMID: 31837959, DOI: 10.1016/s2352-3026(19)30203-0.Peer-Reviewed Original ResearchConceptsAcute myeloid leukemiaHigh-risk acute myeloid leukemiaTherapy-related acute myeloid leukemiaSecondary acute myeloid leukemiaPhase 2 trialPlatelet count recoveryInduction chemotherapyComplete remissionMyeloid leukemiaUntreated patientsEligible patientsCount recoveryDana-Farber/Harvard Cancer CenterEastern Cooperative Oncology Group performance statusUntreated acute myeloid leukemiaActivity of alisertibAdverse-risk karyotypeCommon grade 3Previous myelodysplastic syndromeTreatment-related deathsProportion of patientsPromising therapeutic targetComposite remissionFebrile neutropeniaOral alisertib